Loading
Obesity / Overweight / Chronic Weight Management · Phase 3 Trial
ClinicalTrials.gov · August 14, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a Phase 3 registry record for a global, double-blind, placebo-controlled trial of ASC30 (once-daily oral) in adults with obesity or overweight and type 2 diabetes, with estimated enrollment of 1560 participants and primary outcome of percent change in body weight at Week 72. No results have been reported in this registry record; the trial is actively recruiting.
Phase 3, Interventional, Randomized, Parallel, Triple masking, Treatment purpose. Obesity, Overweight, Chronic Weight Management, Type 2 Diabetes Mellitus; age from 18 Years. Intervention: ASC30 Cohort 1; ASC30 Cohort 2; ASC30 Cohort 3. Compared with: Placebo Cohort 4 — Placebo Comparator. n = 1,560. 136 sites across 6 countries.
This is a Phase 3 registry record for a global, double-blind, placebo-controlled trial of ASC30 (once-daily oral) in adults with obesity or overweight and type 2 diabetes, with estimated enrollment of 1560 participants and primary outcome of percent change in body weight at Week 72. No results have been reported in this registry record; the trial is actively recruiting.
This is a registry record only; no efficacy, safety, or tolerability results are reported. No information provided on blinding verification, dropout rates, adverse events, or subgroup analyses.
The source did not state who this applies to in practice.
This is a clinical trial registry record with no reported results; the study is actively recruiting and outcomes have not yet been assessed or published.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07743450). This is a study registration, not published results. Lead sponsor: Ascletis Pharma (China) Co., Limited. Recruitment status: RECRUITING. Phase: PHASE3. Study type: INTERVENTIONAL. Enrollment: 1560 participants (ESTIMATED). Conditions: Obesity, Overweight, Chronic Weight Management, Type 2 Diabetes Mellitus. Interventions: DRUG: ASC30 tablets A1; DRUG: Placebo. Primary outcome measures: Percent change from baseline in body weight , Baseline to Week 72. Brief summary: Study ASC30-302 (AURORA-2) is a Phase III, global, multicenter, randomized, double-blind, placebo-controlled study to investigate the long-term efficacy, safety, and tolerability of three maintenance doses of once-daily oral ASC30 compared with placebo in participants with obesity or overweight and T2DM.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.